UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 219

Sortiert nach

Should tirzepatide be considered for early management in type 2 diabetes? Pros and cons

Expert opinion on pharmacotherapy, 2023-10, Vol.ahead-of-print (ahead-of-print), p.1-4

2023

Volltextzugriff (PDF)

Glucagon-like peptide-1 receptor agonists for improving cardiorenal outcomes in type 1 diabetes mellitus?

Endocrine, 2023-04, Vol.80 (1), p.232-233

2023

Volltextzugriff (PDF)

Contrast-Associated Acute Kidney Injury: More Frequent Among Patients With Diabetic Foot Ulcers

Angiology, 2023-08, Vol.74 (7), p.609-610

2023

Volltextzugriff (PDF)

Double Diabetes: A Growing Problem Requiring Solutions

Experimental and clinical endocrinology & diabetes, 2022-04, Vol.130 (4), p.268

2022

Volltextzugriff (PDF)

The new dual gastric inhibitory peptide/glucagon‐like peptide 1 agonist tirzepatide in type 2 diabetes: Is the future bright?

Diabetes/metabolism research and reviews, 2021-11, Vol.37 (8), p.e3503-n/a

2021

Volltextzugriff (PDF)

Effect of tirzepatide on the risk of diabetic retinopathy in type 2 diabetes

Diabetes, obesity & metabolism, 2024-06, Vol.26 (6), p.2497-2500

2024

Volltextzugriff (PDF)

SGLT2 inhibitors: A groundbreaking class of cardiovascular drugs, but who benefits most?

International journal of cardiology, 2024-10, Vol.412, p.132326, Article 132326

2024

Volltextzugriff (PDF)

Are SGLT-2 inhibitors “the elephant in the room” of non-diabetic glomerulonephritis? Considerations about the background immunosuppressive treatment

International urology and nephrology, 2023-12, Vol.55 (12), p.3281-3282

2023

Volltextzugriff (PDF)

Diabetic kidney disease in type 1 diabetes: challenges and differences from type 2 diabetes

Metabolism, clinical and experimental, 2024-02, Vol.151, p.155763-155763, Article 155763

2024

Volltextzugriff (PDF)

Beta-Catenin Signaling Pathway: Perhaps We Should Start Exploring it for Diabetic Foot Ulcer Healing?

International journal of lower extremity wounds, 2023-09, Vol.22 (3), p.441-443

2023

Volltextzugriff (PDF)

Potential New Therapeutic Implications of Semaglutide: New Colours of the Rainbow?

Diabetes therapy, 2024-01, Vol.15 (1), p.13-18

2024

Volltextzugriff (PDF)

Ezetimibe and Insulin Resistance

Current vascular pharmacology, 2022-01, Vol.20 (4), p.315

2022

Volltextzugriff (PDF)

One-hour Post-load Plasma Glucose Cut-off Value for Diagnosing Diabetes: Do the New Data Bring us Closer to the Answer?

Experimental and clinical endocrinology & diabetes, 2022-05, Vol.130 (5), p.353

2022

Volltextzugriff (PDF)

Has the time come to step up to “triple therapy” for the treatment of diabetic kidney disease?

Diabetes research and clinical practice, 2023-07, Vol.201, p.110726-110726, Article 110726

2023

Volltextzugriff (PDF)

Reduced Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma in Type 2 Diabetes Mellitus: Will Metformin Never Stop Its Pleasant Surprises?

Advances in therapy, 2022-06, Vol.39 (6), p.2283-2286

2022

Volltextzugriff (PDF)

Effect of sodium-glucose cotransporter-2 inhibitors on continuous glucose monitoring metrics, as adjunctive to insulin in adults with type 1 diabetes mellitus: a meta-analysis of randomized controlled trials

Metabolism, clinical and experimental, 2024-04, Vol.153, p.155791-155791, Article 155791

2024

Volltextzugriff (PDF)

Effectively addressing cardiovascular risk in people with metabolic-dysfunction associated fatty liver disease: not yet ready for prime time

Expert opinion on pharmacotherapy, 2024-02, Vol.25 (2), p.123-126

2024

Volltextzugriff (PDF)

COVID-19 and sulfonylureas: A reminder of the pleiotropic actions of an old class of drugs just before their swansong

Metabolism, clinical and experimental, 2022-08, Vol.133, p.155221-155221, Article 155221

2022

Volltextzugriff (PDF)

Tirzepatide use and the risk of cancer among individuals with type 2 diabetes mellitus: A meta-analysis of randomized controlled trials

Diabetes research and clinical practice, 2024-07, Vol.213, p.111758, Article 111758

2024

Volltextzugriff (PDF)

Effect of tirzepatide on blood pressure levels in overweight/obese individuals without diabetes

European journal of internal medicine, 2024-03, Vol.121, p.155-156

2024

Volltextzugriff (PDF)

Could cardiorenal benefits of sodium-glucose co-transporter 2 inhibitors be extended to type 1 diabetes mellitus?

Journal of diabetes and its complications, 2022-11, Vol.36 (11), p.108338-108338, Article 108338

2022

Volltextzugriff (PDF)

Effect of semaglutide versus other glucagon-like peptide-1 receptor agonists on cardio-metabolic risk factors in patients with type 2 diabetes: A systematic review and meta-analysis of head-to-head, phase 3, randomized controlled trials

Journal of diabetes and its complications, 2023-08, Vol.37 (8), p.108529-108529, Article 108529

2023

Volltextzugriff (PDF)

Efficacy and safety of once‐weekly versus once‐daily basal insulin analogues in the treatment of type 2 diabetes mellitus: A systematic review and meta‐analysis

Diabetes, obesity & metabolism, 2023-12, Vol.25 (12), p.3648-3661

2023

Volltextzugriff (PDF)

Immune checkpoint inhibitors-induced diabetes mellitus: a growing clinical presentation requiring our attention

Expert opinion on drug safety, 2022-11, Vol.21 (11), p.1337-1339

2022

Volltextzugriff (PDF)

GLP-1 Receptor Agonists and Type 1 Diabetes - Where Do We Stand?

Current pharmaceutical design, 2015-01, Vol.21 (36), p.5292

2015

Volltextzugriff (PDF)

1 – 25 von 219

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(160)
Mit Volltextzugriff
(194)

Publikationsform

Sprache

Englisch
(215)
Japanisch
(9)
Serbian
(6)
Deutsch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(7)

Menü

Weitere Dienste

Einstellungen

Should tirzepatide be considered for early management in type 2 diabetes? Pros and cons

Glucagon-like peptide-1 receptor agonists for improving cardiorenal outcomes in type 1 diabetes mellitus?

Contrast-Associated Acute Kidney Injury: More Frequent Among Patients With Diabetic Foot Ulcers

Double Diabetes: A Growing Problem Requiring Solutions

The new dual gastric inhibitory peptide/glucagon‐like peptide 1 agonist tirzepatide in type 2 diabetes: Is the future bright?

Effect of tirzepatide on the risk of diabetic retinopathy in type 2 diabetes

SGLT2 inhibitors: A groundbreaking class of cardiovascular drugs, but who benefits most?

Are SGLT-2 inhibitors “the elephant in the room” of non-diabetic glomerulonephritis? Considerations about the background immunosuppressive treatment

Diabetic kidney disease in type 1 diabetes: challenges and differences from type 2 diabetes

Beta-Catenin Signaling Pathway: Perhaps We Should Start Exploring it for Diabetic Foot Ulcer Healing?

Potential New Therapeutic Implications of Semaglutide: New Colours of the Rainbow?

Ezetimibe and Insulin Resistance

One-hour Post-load Plasma Glucose Cut-off Value for Diagnosing Diabetes: Do the New Data Bring us Closer to the Answer?

Has the time come to step up to “triple therapy” for the treatment of diabetic kidney disease?

Reduced Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma in Type 2 Diabetes Mellitus: Will Metformin Never Stop Its Pleasant Surprises?

Effect of sodium-glucose cotransporter-2 inhibitors on continuous glucose monitoring metrics, as adjunctive to insulin in adults with type 1 diabetes mellitus: a meta-analysis of randomized controlled trials

Effectively addressing cardiovascular risk in people with metabolic-dysfunction associated fatty liver disease: not yet ready for prime time

COVID-19 and sulfonylureas: A reminder of the pleiotropic actions of an old class of drugs just before their swansong

Tirzepatide use and the risk of cancer among individuals with type 2 diabetes mellitus: A meta-analysis of randomized controlled trials

Effect of tirzepatide on blood pressure levels in overweight/obese individuals without diabetes

Could cardiorenal benefits of sodium-glucose co-transporter 2 inhibitors be extended to type 1 diabetes mellitus?

Effect of semaglutide versus other glucagon-like peptide-1 receptor agonists on cardio-metabolic risk factors in patients with type 2 diabetes: A systematic review and meta-analysis of head-to-head, phase 3, randomized controlled trials

Efficacy and safety of once‐weekly versus once‐daily basal insulin analogues in the treatment of type 2 diabetes mellitus: A systematic review and meta‐analysis

Immune checkpoint inhibitors-induced diabetes mellitus: a growing clinical presentation requiring our attention

GLP-1 Receptor Agonists and Type 1 Diabetes - Where Do We Stand?

Suchergebnisse filtern